Sinoway Industrial Co., Ltd

Date: 13th May 2016
Sinoway Industrial Co.,Ltd is a famous China liraglutide manufacturer and supplier,Website:, welcome to buy GMP and EP liraglutide from us and check the price with us.1.Product Description:1.Product NameLiraglutide2.Appereance:White to off-white crystalline powder3.Molecular Formula C172H265N43O514.Cas. No. 204656-20-25.Molecular Weight 3751.206.Storage 2~8?2.Introduction:Liraglutide(NN2211) is a long-actingglucagon-like peptide-1 receptor agonist, binding to the same receptors as does theendogenousmetabolichormoneGLP-1that stimulatesinsulinsecretion.3.Specification:Product Name:LiraglutideSequence:H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys[N6-[N-(1-oxohexadecyl)-L-?-glutamyl]--Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OHLot No.:140601Release Date:2014-6-13TestSpecificationResultsAppearance:White to off-white crystalline powder or lumpsWhite powderIdentity:3751.2?1.03751.1Purity (By HPLC) :Not Less than 98.0%;99.51%Residual solvents:?0.25%total; ?0.1%individual;?0.01%CH2CNCompliesRelated PeptideTotal Impurity ? 2.0%Largest Single Impurity ? 1.0%TI =0.41%LSI =0.25%Peptide Content:Not Less than 85.0%87.7%Water (K.F.):Not more than 5%4.2%Acetate acid:Not more than 10%8.1%Bacterial EndotoxinsNot more than 50IU/mgComplies4.Function and Usage:Type 2 diabetesLiraglutide improves control ofblood glucose.It reduces meal-relatedhyperglycemia(for 24 hours after administration) by increasinginsulinsecretion (only) when required by increasing glucose levels, delaying gastric emptying, and suppressing prandialglucagonsecretion.In common to various degrees with other GLP-1 receptor agonists, liraglutide has advantages over more traditional therapies for type 2 diabetes:1).It acts in a glucose-dependent manner, meaning it will stimulate insulin secretion only when blood glucose levels are higher than normal, preventing "overshoot". Consequently, it shows negligible risk ofhypoglycemia.2).It has the potential for inhibitingapoptosisand stimulating regeneration ofbeta cells(seen in animal studies).3).It decreases appetite and inhibits body weight gain, as shown in a head-to-head study versusglimepiride.4).It lowers bloodtriglyceridelevels.ObesityLiraglutide has been approved as an injectable adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients. The specified criteria are an initial body mass index (BMI) of 30kg/m2 or greater (obese), or 27kg/m2 or greater (overweight), in the presence of at least one weight-related comorbid condition (e.g.hypertension, type 2 diabetes mellitus, or dyslipidemia). In late 2014, data were reported from the SCALE™ Obesity and Prediabetes trial,which is a randomised, double-blind, placebo-controlled, multinational trial in non-diabetic people with obesity and non-diabetic people who are overweight with comorbidities. In this phase 3a trial, there were 3,731 participants randomised to treatment with liraglutide 3mg or placebo, both in combination with diet and exercise. Those who completed the 56-week trial achieved an average weight loss of 9.2%, to be compared with a 3.5% reduction in the placebo group.
Latest News
Contact Information



16/F., Huicheng Comm. Complex, No.839 Xiahe Rd, Xiamen, China
Xiamen, 361004


Contact Form